

Application No.: 09/991,470
Attorney Docket No.: TNX99-05-01
Page 2

comprising administering a composition comprising a vector comprising a nucleic acid encoding an anti-IgE antibody or IgE binding fragment thereof.

- 19/ 30. (NEW) The method of claim ¹⁸29, wherein the anti-IgE antibody is Hu901.
- 20/ 31. (NEW) A method of inducing a host cell to express an scFv fragment of the anti-IgE antibody of claim ¹⁷28, comprising administering a composition comprising a vector comprising a nucleic acid encoding the scFv anti-IgE.
- 21/ 32. (NEW) The method of claim ²⁰31, wherein nucleic acid encodes an scFv of Hu901.
- 22/ 33. (NEW) A method of suppressing or attenuating an IgE-mediated allergic disease comprising administering a composition comprising a vector comprising a nucleic acid encoding an anti-IgE antibody or IgE-binding fragment thereof, wherein said anti-IgE antibody inhibits or blocks the binding of IgE to the high affinity IgE receptor.
- 23/ 34. (NEW) The method of any one of claims ¹⁷28 to ²²33, wherein the vector is an adenoviral vector with a human cytomegalo virus promoter for expression of the anti-IgE antibody.--

REMARKS

Applicants have cancelled claims 1-27 without prejudice or disclaimer to the subject matter contained therein. New claims 28-34 have been added. Support for these claims may be found in the specification as a whole and in claims 1-27. No new matter has been introduced by the addition of these claims.